NSE · CIPLA

Cipla share price, financials and monitoring

Cipla sells pharmaceutical products across India and international markets. Product launches, geographic mix, regulatory disclosures and research spending shape the business.

HealthcarePharmaceuticals & BiotechnologyCorporatePage reviewed 5 Nov 2026
Last NSE close₹1,402Bhavcopy · 4 Nov 2026 · end of day
Market cap₹1,13,261 crCalculated on 4 Nov 2026
P/E39.1×TTM EPS through 30 Sept 2026
P/B3.2×As of 4 Nov 2026

Dates and sources

The last NSE bhavcopy close is dated 4 Nov 2026. Valuation observations are dated 4 Nov 2026. The latest financial quarter ends 30 Sept 2026. These are separate observation dates, not live quotes. Financial reporting basis: consolidated.

Read the Nifty drivers report · Understand index funds and ETFs · NSE daily reports

Latest reported evidence

Year ended 2026-03-31 and the latest quarter

The tables use one reporting basis across the displayed history, preferring consolidated where sufficient history is available. Each row identifies its period and original filing. Profit is attributable to owners where disclosed; otherwise total profit is labelled.

Year ended 2026-03-31 Revenue₹28,163 crYear ended 31 Mar 2026
Year ended 2026-03-31 PAT₹3,879 crAttributable to owners · 31 Mar 2026
Latest-quarter PAT₹878 crQuarter ended 30 Sept 2026
ROCE11.4%Ratio observation: 30 Sept 2026
Annual observations

Revenue history

A rising top line is evidence of scale, not proof of value creation. Read it with profit, capital efficiency, cash conversion and the business-specific guideposts above.

How to read these figures

₹ crore values are presented as filed or normalized from company/exchange financial results. Banks and NBFCs use total income because interest is part of their operating business. Industrial companies use revenue where available.

Historical values can be restated. EPS retains the share basis in its original filing and may not be directly comparable across corporate actions. Gaps in annual periods remain gaps; the source and reporting basis are retained.

Year endedRevenuePATReported EPSBasisEvidence
Year ended 2022-03-3131 Mar 2022₹21,763 cr₹2,517 cr31.2Consolidated · PAT: ownersFiling ↗
Year ended 2023-03-3131 Mar 2023₹22,753 cr₹2,802 cr34.72Consolidated · PAT: ownersFiling ↗
Year ended 2024-03-3131 Mar 2024₹25,774 cr₹4,122 cr51.05Consolidated · PAT: ownersFiling ↗
Year ended 2025-03-3131 Mar 2025₹27,548 cr₹5,273 cr65.29Consolidated · PAT: ownersFiling ↗
Year ended 2026-03-3131 Mar 2026₹28,163 cr₹3,879 cr48.03Consolidated · PAT: ownersFiling ↗
Quarterly results

Eight reported quarters

Publication date is shown separately from the period end. A June quarter was not knowable on 30 June; it entered the public record only when the company filed it.

Quarter endedRevenuePATReported EPSPublishedEvidence
30 Sept 2026Consolidated · PAT: owners₹7,404 cr₹878 cr10.8627 Oct 2026Filing ↗
30 Jun 2026Consolidated · PAT: owners₹7,119 cr₹789 cr9.7723 Jul 2026Filing ↗
31 Mar 2026Consolidated · PAT: owners₹6,541 cr₹555 cr6.8713 May 2026Filing ↗
31 Dec 2025Consolidated · PAT: owners₹7,074 cr₹676 cr8.3723 Jan 2026Filing ↗
30 Sept 2025Consolidated · PAT: owners₹7,589 cr₹1,351 cr16.7330 Oct 2025Filing ↗
30 Jun 2025Consolidated · PAT: owners₹6,957 cr₹1,298 cr16.0725 Jul 2025Filing ↗
31 Mar 2025Consolidated · PAT: owners₹6,730 cr₹1,222 cr15.1313 May 2025Filing ↗
31 Dec 2024Consolidated · PAT: owners₹7,073 cr₹1,571 cr19.4528 Jan 2025Filing ↗
Returns and profitability

Use the metric that fits the business.

ROCE is not shown for banks and NBFCs because deposits and borrowings are operating raw material rather than ordinary financing. Missing or inapplicable values remain unavailable.

ROCE11.4%Period ended 30 Sept 2026
ROE8.5%Period ended 30 Sept 2026
ROA6.9%Period ended 30 Sept 2026
Net profit margin10.0%TTM through 30 Sept 2026
EBIT margin13.6%TTM through 30 Sept 2026
Profit growth-46.8%YoY through 30 Sept 2026
Ownership

Who owns the company?

Shareholding is shown from the latest available filing. Institutional subtotals depend on the filing taxonomy and are labelled by their source basis.

Latest ownership period30 Sept 2026
Institution basisFiled institutional subtotal
Promoter and group29.2%Filed for 30 Sept 2026
FII holding20.3%+0.04 pp QoQ
DII holding34.9%+0.31 pp QoQ
Forensic context

Profit is only one part of the evidence.

These are investigation prompts, not pass-or-fail verdicts. Business model, working-capital structure and reporting basis determine how each value should be interpreted.

Cash conversion0.7×CFO divided by TTM PAT
CFO to PAT1.0×FY ended 31 Mar 2026
Accruals ratio-0.1%Lower is generally cleaner, but context matters
Borrowings₹258 crFY ended 31 Mar 2026
Observation scope

Dated evidence, linked to its source.

The page shows selected annual and quarterly periods. The financial tables, market observations and ownership figures can have different dates.

Displayed annual history31 Mar 2022 to 31 Mar 2026
Latest financial quarter30 Sept 2026
NSE closing price4 Nov 2026
Page reviewed5 Nov 2026
Questions investors ask

Cipla FAQ

What does Cipla do?

Cipla sells pharmaceutical products across India and international markets. Product launches, geographic mix, regulatory disclosures and research spending shape the business.

What should investors monitor for Cipla?

Important operating evidence includes india and overseas mix, product launches, regulatory disclosures, research spending. These are research guideposts, not automatic trading signals.

Are the Cipla financials consolidated or standalone?

Altys prefers consolidated financials when available and labels the reporting basis in each table. The latest annual row on this page is consolidated.

Does Altys recommend buying or selling Cipla?

No. Altys provides sourced financial data, research context and monitoring infrastructure. It does not issue a buy, sell or hold recommendation on this page.

Continuous research

Research Cipla once. Keep watching what changes.

Altys can connect new results, filings, concalls, guidance, ownership and company-specific KPIs with the investment team’s original thesis and portfolio context.